Marshall Wace North America
APTO

Marshall Wace North America’s Aptose Biosciences, Inc. APTO Stock Holding History

Marshall Wace North America’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-75
Closed -$201K – 1895
2021
Q1 		$201K Buy
+75
New +$149K ﹤0.01% 1409
2020
Q3 		– Sell
-63
Closed -$178K – 1554
2020
Q2 		$178K Buy
+63
New +$203K ﹤0.01% 1078

Other funds holding APTO

DRW Securities
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $755M AUM 11.28% 1-Year Est. Return

Marshall Wace North America's APTO Position: Q2 2021 in Review

Marshall Wace North America sold out of Aptose Biosciences, Inc. (APTO) in Q2 2021, closing a stake of 75 shares — an estimated $201K sold.

Marshall Wace North America first reported a position in APTO in Q2 2020 and held it in 2 quarters. The position peaked at $201K in Q1 2021. 63 funds tracked by Wall St. Rank hold APTO as of Q2 2021.

  • Marshall Wace North America reported no remaining Aptose Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 75 Aptose Biosciences, Inc. shares in Q2 2021, an estimated $201K.
  • Marshall Wace North America first reported a position in Aptose Biosciences, Inc. in Q2 2020 and held it in 2 quarters.
  • Marshall Wace North America's Aptose Biosciences, Inc. position peaked at $201K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.